Jakafi 5 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRP5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,586
Award facts
- Contract value 100% obligated
- $49,586.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $49,586.32 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for 60 tablets of Jakafi 5 mg, with an ultimate completion date of December 15, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award IDC valued at $499,999,999 through December 31, 2036.
Jakafi (ruxolitinib) is a specialty pharmaceutical used in the treatment of myelofibrosis and other hematologic conditions, reflecting the broad therapeutic range that DMS Pharmaceutical Group supplies to Department of Defense healthcare facilities worldwide. The company's established track record of delivering diverse pharmaceutical products—from oncology treatments and biologics to emergency medications and routine pharmaceuticals—positions it as a critical supplier within the federal military medical system. No subcontractors were identified on this award, with DLA serving as the sole funding agency.
Quick answers
Who was awarded contract SPE2DR26FCRP5?
SPE2DR26FCRP5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 12, 2025.
How much is contract SPE2DR26FCRP5 worth?
The government has obligated $49,586 on SPE2DR26FCRP5.
Is contract SPE2DR26FCRP5 an order under another contract?
Yes. SPE2DR26FCRP5 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRP5 competed?
The extent of competition for SPE2DR26FCRP5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award